Comparative Pharmacology
Head-to-head clinical analysis: MACRILEN versus PEPTAVLON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MACRILEN versus PEPTAVLON.
MACRILEN vs PEPTAVLON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MACRILEN (macimorelin) is a synthetic growth hormone secretagogue receptor (GHS-R) agonist that stimulates growth hormone (GH) release from the anterior pituitary. It mimics the action of ghrelin, enhancing GH secretion through GHS-R activation.
Peptavlon is a synthetic analogue of human parathyroid hormone (PTH 1-34) that acts as a diagnostic agent by stimulating osteoblast activity and increasing serum calcium levels through PTH receptor activation.
1 mg subcutaneously once daily, titrated as needed to a maximum of 2 mg daily.
Intravenous: 0.5 mg/kg every 6 hours; maximum single dose 40 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 3 hours (range 2.5–4.5 hours) in healthy adults. This short half-life supports its use for diagnostic testing, with rapid clearance after stimulation of growth hormone release.
Terminal elimination half-life: 8 hours (range 6-10 hours) in adults; prolonged to 12-15 hours in moderate renal impairment (CrCl 30-50 mL/min)
Primarily renal; approximately 90% of the administered dose is excreted unchanged in urine within 24 hours. Less than 5% is metabolized, with metabolites also eliminated renally. Fecal excretion is negligible (<2%).
Renal: 65% (unchanged), Biliary: 25% (metabolites), Fecal: 10%
Category C
Category C
Diagnostic Agent
Diagnostic Agent